GLP-1 Receptor Agonists Show Potential Cancer Prevention Benefits in Preclinical and Observational Studies (sciencenews.org)

• GLP-1 drugs (Ozempic, Wegovy) associated with lower risk of colorectal and pancreatic cancers in observational studies.
• Proposed mechanisms include weight loss, anti-inflammatory effects, and direct tumor suppression.
• Irish health policymakers may consider these benefits in reimbursement and clinical guidelines updates.

"Recent studies suggest GLP-1 drugs like Ozempic may reduce the risk of certain cancers, including colorectal and pancreatic. However, definitive clinical trials are lacking. The findings could influence drug reimbursement and clinical guidelines in Ireland."